Table 4.

Response rates, overall and by dosing regimen

Response category	All patients (N = 64)	Receiving lower dosing regimens* (N = 35)	Receiving higher dosing regimens† (N = 29)
	n (%)
ORR	30 (47)	13 (37)	17 (59)
CR	1 (1.6)	0	1 (3)
PR	25 (41)	11 (31)	14 (48)
MR‡	4 (6)	2 (6)	2 (7)
SD	25 (39)	16 (46)	9 (31)
PD	4 (6)	4 (11)	0
NE	5 (8)	2 (6)	3 (10)

NE, not evaluable; SD, stable disease.

^*Dosing regimens include 150 mg BID for 21 d with 7 d off every 4 wk, or 150 mg QD, 50 mg BID, and 100 mg BID continuously.

^†Dosing regimens include 300 mg QD, 150 mg BID, 200 mg BID, and 350 mg BID continuously.

^‡Category for WM only.